Blastomyces Antibody by EIA, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Detection of antibodies in patients having blastomycosis
Enzyme Immunoassay (EIA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Blastomyces Ab, EIA, S
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 1 mL
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The dimorphic fungus, Blastomyces dermatitidis, causes blastomycosis. When the organism is inhaled, it causes pulmonary disease-cough, pain, and hemoptysis, along with fever and night sweats. It commonly spreads to the skin, bone, or internal genitalia where suppuration and granulomas are typical. Occasionally, primary cutaneous lesions after trauma are encountered; however, this type of infection is uncommon.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
A positive result indicates that IgG and/or IgM antibodies to Blastomyces were detected. The presence of antibodies is presumptive evidence that the patient was or is currently infected with (or exposed to) Blastomyces.
A negative result indicates that antibodies to Blastomyces were not detected. The absence of antibodies is presumptive evidence that the patient was not infected with Blastomyces. However, the specimen may have been obtained before antibodies were detectable or the patient may be immunosuppressed. If infection is suspected, another specimen should be drawn 7 to 14 days later and submitted for testing.
All specimens testing equivocal will be repeated. Specimens testing equivocal after repeat testing should be submitted for further testing by another conventional serologic test (eg, SBL/8237 Blastomyces Antibody by Immunodiffusion, Serum).
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A negative result does not rule out blastomycosis.
Cross-reactivity may occur with other fungal infections such as Aspergillus, Coccidioides, or Histoplasma.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Kaufman L, Kovacs JA, Reiss E: Clinical immunomycology. In Manual of Clinical and Laboratory Immunology. Edited by NL Rose, E Conway-de Macario, JD Folds, et al. Washington, DC, ASM Press, 1997, pp 588-589
Method Description Describes how the test is performed and provides a method-specific reference
The Omega Blastomyces Total Antibody EIA assay uses microwells coated with purified Blastomyces yeast-phase antigen. Patient specimen is diluted in diluent buffer and incubated in the coated microwell. If present, IgG and/or IgM antibodies will bind to the antigen. The microwells are washed to remove unbound serum components. A secondary antibody, rabbit anti-human IgG and IgM antibody conjugated to horseradish peroxidase, is added to the microwell and incubated. The secondary antibody will bind to the antibody-anitigen complexes. The microwells are washed to remove unbound conjugate. Substrate solution containing urea peroxide and tetramethylbenzidine is added to the microwells causing a color change. After a final incubation period, stop solution is added to the microwells and the color change is quantified by measuring the optical density (OD). Sample OD readings are compared to calibrator cutoff OD readings to determine results. (Package insert: Omega Blastomyces Total Antibody EIA, Immuno-Mycologics, Inc., 2700 Technology Place, Norman, OK)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday, Sunday; 9 a.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|SBLAS||Blastomyces Ab, EIA, S||7816-2|